Abstract 14501: Empagliflozin Improves 24-Hour Blood Pressure Profiles in Patients With Type 2 Diabetes and Hypertension

Ilkka Tikkanen,Kirsi Narko,Cordula Zeller,Alexandra Green,Afshin Salsali,Uli C. Broedl,Hans J. Woerle

Abstract 14501: Empagliflozin Improves 24-Hour Blood Pressure Profiles in Patients With Type 2 Diabetes and Hypertension

2013

Ilkka Tikkanen
Kirsi Narko
Cordula Zeller
Alexandra Green
Afshin Salsali
Uli C. Broedl
Hans J. Woerle

A Phase III randomized placebo (PBO)-controlled trial investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin (EMPA) in patients with type 2 diabetes (T2DM) and hypertension. Pati...

Keywords:

Placebo
Internal medicine
EMPA
Diabetes mellitus
SGLT2 Inhibitor
Cardiology
Empagliflozin
Type 2 diabetes
Medicine
Blood pressure
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations